The potential of PEGylated Protein Therapeutics

Posted by sunnyfang1419 on February 12th, 2020

Surge in prevalence of chronic diseases across the globe is anticipated to significantly drive the growth of the PEGylated protein therapeutics market. Furthermore, benefits such as, extended half-life and increased bioavailability offered by PEGylated protein therapeutics is the key factor that augments the market growth.

PEGylation is a process of addition of active polyethylene glycol to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. The chemical modification due to PEGylation results in various advantages, such as an extended half-life of a drug along with low toxicity and increased proteolytic protection, over the non-modified protein therapeutics. PEGylated protein therapeutics are used in multiple conditions such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohns disease, and others.

The factors that drive the growth of the global PEGylated protein therapeutics market are increase in prevalence of chronic diseases, advantages offered by PEGylation, and strong presence of pipe line drugs are. However, high cost related to drug development and launch of generics during the forecast period are expected to impede the market growth. In addition, high market potential in the untapped emerging economies and increase in adoption of PEGylated protein therapeutics are expected to provide many opportunities during the forecast period.